Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06222762
Other study ID # 29BRC23.0022
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 13, 2024
Est. completion date September 9, 2026

Study information

Verified date January 2024
Source University Hospital, Brest
Contact Jacques Mansourati, MD, PhD
Phone +33298347405
Email jacques.mansourati@chu-brest.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

France has one million people with heart failure (HF). Exercise intolerance, characterised by dyspnoea, is the main clinical symptom in HF patients and a key determinant of reduced quality of life. In addition to drug and surgical treatments, cardiac rehabilitation programmes have shown benefits in heart failure patients. Lasting at least 3 weeks, these programmes improve physical abilities, quality of life and reduce the risk of hospitalisation for heart failure patients. To date, the real challenge is no longer to prove the benefits of cardiac rehabilitation, but to find solutions to maintain its long-term effects. The transition between the end of the supervised programmes in the centre and the return home is a difficult phase for the majority of patients who do not continue regular physical activity and thus quickly lose the benefits of the programme. To help maintain the benefits of cardiac rehabilitation, some centres offer patients programmes to continue physical activity during phase III. Although these options are often beneficial in the first few months after the end of rehabilitation compared to control groups, the long-term results are mixed. These results imply that one of these maintenance options may not be suitable for all patients. It is therefore important to propose a personalised post-rehabilitation follow-up involving the patient in the choice of physical activities to optimise the maintenance of long-term benefits. We hypothesise that patients who receive personalised support from a sport and health professional following rehabilitation maintain long-term benefits compared to a control group who do not receive this support.


Recruitment information / eligibility

Status Recruiting
Enrollment 90
Est. completion date September 9, 2026
Est. primary completion date September 9, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Diagnosis of stable heart failure with NYHA stage I, II or III - Participation in a cardiac rehabilitation programme - Patient agreement - Patient of legal age - Patient affiliated to the Social Security Exclusion Criteria: - Patient refusal - Minor patients - Subjects under guardianship or curatorship - Subjects over 80 years of age at the time of inclusion

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Experimental arm
Personalized follow-up in adapted physical activities

Locations

Country Name City State
France CHU de Brest Brest
France Fondation ILDYS Brest

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary To compare the evolution of the level of physical activity 12 months after a cardiac rehabilitation programme between patients benefiting from personalised support at the end of the rehabilitation and a control group benefiting from the usual management. The primary endpoint will be the difference in mean daily steps measured by accelerometry (over 7 days) at the start of the rehabilitation course (Visit 1) and after 12 months of personalised follow-up (Visit 4). 12 months
Secondary To compare between the experimental group and the control group, the evolution 12 months after a cardiac rehabilitation programme of time spent in each level of activity : Levels of activity :
Sedentary time (min/day)
Time spent in activity with light intensity (min/day)
Time spent in activity with moderate intensity (min/day)
Time spent in activity with vigorous intensity (min/day)
12 months
Secondary To compare physical capacities measured using the 6-minute walk test between the experimental group and the control group, the evolution 12 months after a cardiac rehabilitation programme The 6-minute walk test: total walked distance (in metres) The test will be performed twice, the best performance will be kept as reference value. 12 months
Secondary To compare physical capacities measured using the endurance test between the experimental group and the control group, the evolution 12 months after a cardiac rehabilitation programme The endurance test: endurance time (in seconds) During this test, the patient will be asked to walk at a constant speed (mean speed measured at the 6 minute walking test). If the patient can walk at the requested speed for more than 10 minutes, a second test is performed. The imposed speed is increased by 10% for this second test. 12 months
Secondary To compare physical capacities measured using the chair getting-up test between the experimental group and the control group, the evolution 12 months after a cardiac rehabilitation programme the total number of time when the patient gets up and sit down on a chair during 1 minute is recorded 12 months
Secondary To compare physical capacities measured using the hand-grip test between the experimental group and the control group, the evolution 12 months after a cardiac rehabilitation programme The hand-grip test: maximal force (in kg for both hands). the patient will use a dynamometer Hand-grip. The test will be performed 3 times per visit. The force (in Newton) is recorded, the best performance is kept as the reference value 12 months
Secondary To compare physical capacities measured using the incremental ergocycle test between the experimental group and the control group, the evolution 12 months after a cardiac rehabilitation programme The incremental ergocycle test: maximal power (watts) and VO2 (mL.min.kg-1) The test is performed on a ergocycle. 12 months
Secondary To compare the evolution of dyspnea scores 12 months after a cardiac rehabilitation programme between the experimental group and the control group Dyspnea-12 questionnaire dyspnea scores DYSPNEA 12 : The DYSPNEA 12 comprised of 12 different breathlessness descriptors with each scored on a four-item scale (none-0, mild-1, moderate2, severe-3). Item scores are summed (D-12 Total) and can be divided into sub-scores reflecting Physical and Affective domains. 12 months
Secondary To compare the psychological dimensions (motivation) between the experimental group and the control group, the evolution 12 months after a cardiac rehabilitation programme EMAPS questionnaire EMAPS : The questionnaire includes 18 items. The EMAPS is used to evaluate the motivation to practice physical activities. The answer to questions goes from 1 to 7 with 1 (does not match at all) and 7 (matches very strongly). 12 months
Secondary To compare the psychological dimensions (anxiety/depression) between the experimental group and the control group, the evolution 12 months after a cardiac rehabilitation programme HAD questionnaire HAD : The questionnaire includes 7 items for depression and 7 items for anxiety. Each item had been answered by the patient on a four point (0-3) response category so the possible scores ranged from 0 to 21 for anxiety and for depression. A score of 0 to 7 for either subscale could be regarded as being in the normal range, a score of 11 or higher indicating probable presence ('caseness') of the mood disorder and a score of 8 to 10 being just suggestive of the presence of the respective state. 12 months
Secondary To compare the psychological dimensions (quality of life) between the experimental group and the control group, the evolution 12 months after a cardiac rehabilitation programme SF-36 : The Short Form 36 (SF36) is used to evaluate the quality of life. The SF36 scale includes 36 items divided into 8 dimensions (physical functioning, role limitations related to physical health, physical pain, general health, vitality [energy / fatigue) 12 months
Secondary To compare the psychological dimensions (quality of life) between the experimental group and the control group, the evolution 12 months after a cardiac rehabilitation programme EQ5D5L : The questionnaire includes 5 items mobility, personal care, usual activities, pain/discomfort and anxiety/depression. 12 months
Secondary To compare, between groups, the evolution 12 months after a cardiac rehabilitation programme of the physiological adaptations during endurance test Comparison of physiological adaptations assessed in the endurance test
- Ventilatory parameters (minute ventilation, respiratory rate and tidal volume)
12 months
Secondary To compare, between groups, the evolution 12 months after a cardiac rehabilitation programme of the physiological adaptations during endurance test Comparison of physiological adaptations assessed in the endurance test
- Gas exchange (SpO2)
12 months
Secondary To compare, between groups, the evolution 12 months after a cardiac rehabilitation programme of the physiological adaptations during endurance test Comparison of physiological adaptations assessed in the endurance test
- Muscle parameters (HbO2, Hbtot)
12 months
Secondary To compare, between groups, the evolution 12 months after a cardiac rehabilitation programme of the physiological adaptations during endurance test Comparison of physiological adaptations assessed in the endurance test
- Cardio-ventilatory parameters (heart rate in beat/min and electrocardiogram (ECG))
12 months
Secondary To compare, between groups, the evolution 12 months after a cardiac rehabilitation programme of the physiological adaptations during endurance test comparison of physiological adaptations assessed in the incremental test:
- Ventilatory parameters (minute ventilation, respiratory rate and tidal volume)
12 months
Secondary To compare, between groups, the evolution 12 months after a cardiac rehabilitation programme of the physiological adaptations during endurance test comparison of physiological adaptations assessed in the incremental test:
- Gas exchange parameters (SpO2, VO2, VCO2)
12 months
Secondary To compare, between groups, the evolution 12 months after a cardiac rehabilitation programme of the physiological adaptations during endurance test comparison of physiological adaptations assessed in the incremental test:
- Muscle parameters (HbO2, Hbtot, fatigue perception)
12 months
Secondary To compare, between groups, the evolution 12 months after a cardiac rehabilitation programme of the physiological adaptations during endurance test comparison of physiological adaptations assessed in the incremental test:
- Cardiovascular parameters (heart rate in beat/min, electrocardiogram (ECG), systolic and diastolic pression (mmHg)
12 months
Secondary To compare, between groups, the evolution 12 months after a cardiac rehabilitation programme of the endothelial dysfunction : microcirculation - Analyse of skin circulation (laser doppler) with post-occlusive reactive hyperemia et hyperthermia 12 months
Secondary To compare, between groups, the evolution 12 months after a cardiac rehabilitation programme of the endothelial dysfunction : macrocirculation - Analyse by flow-mediated dilatation (FMD) by echography 12 months
Secondary To compare, between groups, the evolution 12 months after a cardiac rehabilitation programme of the endothelial dysfunction : blood markers - Analyses of several blood markers related to endothelial dysfunction, inflammation and/or heart failure : IL-6 ; IL-10; VEGF-A; Ang-1; Ang-2; IL-1ß; TNF-a; MCP-1; IL-8; EGF; E-selectine; I-CAM 1; PECAM-1; VCAM-1; tPA; CRP; VWF; NT-pro-BNP; ET-1 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05654272 - Development of CIRC Technologies
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy